{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:52:12Z","timestamp":1762300332530,"version":"build-2065373602"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010230","name":"Qinghai University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.avsg.2025.06.026","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:50:44Z","timestamp":1751424644000},"page":"299-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bayesian Network Meta-Analysis of Randomized Controlled Trials Comparing the Efficacy of Diverse Interventions in Preventing Portal Venous System Thrombosis Following Splenectomy in Patients with Liver Cirrhosis"],"prefix":"10.1016","volume":"121","author":[{"given":"Yonghao","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunlong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuanhong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haining","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2025.06.026_bib1","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(21)01374-X","article-title":"Liver cirrhosis","volume":"398","author":"Gin\u00e8s","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2025.06.026_bib2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Marrone GFern\u00e1ndez-Iglesias A Hepatic microcirculation and mechanisms of portal hypertension","volume":"16","author":"Gracia-Sancho","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib4","article-title":"Laparoscopic splenectomy with pericardial devascularization for hypersplenism and esophageal variceal hemorrhage due to portal hypertension","volume":"213","author":"Liu","year":"2024","journal-title":"J Vis Exp"},{"key":"10.1016\/j.avsg.2025.06.026_bib5","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.surg.2017.07.016","article-title":"Incidence and predictors of portal and splenic vein thrombosis after pure laparoscopic splenectomy","volume":"162","author":"De'angelis","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.avsg.2025.06.026_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5152\/tjg.2015.0063","article-title":"The incidence and risk factors of portal vein system thrombosis after splenectomy and pericardial devascularization","volume":"26","author":"Wu","year":"2015","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.avsg.2025.06.026_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.amjsurg.2006.06.036","article-title":"Total splenic vein thrombosis after laparoscopic splenectomy: a possible candidate for treatment","volume":"193","author":"Ikeda","year":"2007","journal-title":"Am J Surg"},{"key":"10.1016\/j.avsg.2025.06.026_bib8","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2468-1253(24)00155-9","article-title":"Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies","volume":"9","author":"Elkrief","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jhep.2021.11.004","article-title":"HIntagliata N M Haemostatic alterations and management of haemostasis in patients with cirrhosis","volume":"76","author":"Lisman","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104825","article-title":"What intervention regimen is most effective prevention for Portal venous system thrombosis after splenectomy in cirrhotics patients with Portal hypertension? Systematic review and network meta-analysis","volume":"157","author":"Ding","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.avsg.2025.06.026_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290164","article-title":"Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.avsg.2025.06.026_bib14","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.avsg.2025.06.026_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s42256-020-00287-7","article-title":"An open source machine learning framework for efficient and transparent systematic reviews","volume":"3","author":"Van De Schoot","year":"2021","journal-title":"Nat Machine Intelligence"},{"key":"10.1016\/j.avsg.2025.06.026_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072254","article-title":"Artificial intelligence in systematic reviews: promising when appropriately used","volume":"13","author":"Van Dijk","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.avsg.2025.06.026_bib17","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"10.1016\/j.avsg.2025.06.026_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"10.1016\/j.avsg.2025.06.026_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2025.06.026_bib20","first-page":"35","article-title":"The application effect of rivaroxaban in preventing PVT after splenectomy for liver cirrhosis","volume":"9","author":"Feng","year":"2024","journal-title":"Clin Res Pract"},{"key":"10.1016\/j.avsg.2025.06.026_bib21","first-page":"1644","article-title":"H Early application of low-molecular-weight heparin combined with aspirin to prevent portal vein thrombosis after splenectomy for liver cirrhosis","volume":"37","author":"Xu","year":"2017","journal-title":"J Nanjing Med Univ"},{"key":"10.1016\/j.avsg.2025.06.026_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijsu.2019.02.018","article-title":"Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: a randomized clinical trial","volume":"64","author":"Bai","year":"2019","journal-title":"Int J Surg"},{"key":"10.1016\/j.avsg.2025.06.026_bib23","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1007\/s00464-022-09340-5","article-title":"Early prevention and risk factors analysis of portal vein system thrombosis after laparoscopic splenectomy and pericardial devascularization","volume":"36","author":"Li","year":"2022","journal-title":"Surg Endosc"},{"key":"10.1016\/j.avsg.2025.06.026_bib24","article-title":"Comparison of apixaban and aspirin in preventing portal vein thrombosis after laparoscopic splenectomy for cirrhotic hypersplenism","author":"Shi","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.avsg.2025.06.026_bib25","first-page":"537","article-title":"Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: a randomized clinical trial","volume":"20","author":"Yao","year":"2021","journal-title":"Excli j"},{"key":"10.1016\/j.avsg.2025.06.026_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1503\/cjs.049909","article-title":"Randomized controlled trial to investigate the impact of anticoagulation on the incidence of splenic or portal vein thrombosis after laparoscopic splenectomy","volume":"54","author":"Wang","year":"2011","journal-title":"Can J Surg"},{"key":"10.1016\/j.avsg.2025.06.026_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3324\/haematol.12682","article-title":"The postoperative splenic\/portal vein thrombosis after splenectomy and its prevention--an unresolved issue","volume":"93","author":"Krauth","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.avsg.2025.06.026_bib28","first-page":"2667","article-title":"Consensus for management of portal vein thrombosis in liver cirrhosis(2020,Shanghai)","volume":"36","year":"2020","journal-title":"J Clin Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib29","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0040-1715473","article-title":"New insights into the pathogenesis, risk factors, and treatment of portal vein thrombosis in patients with cirrhosis","volume":"46","author":"Nicoar\u0103-Farc\u0103u","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 1","key":"10.1016\/j.avsg.2025.06.026_bib30","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S0168-8278(12)60004-X","article-title":"EValla D C Management of hepatic vascular diseases","volume":"56","author":"Plessier","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.avsg.2025.06.026_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.21037\/hbsn-22-556","article-title":"Periprocedural management of hemostatic alterations in patients with cirrhosis and vascular liver disorders: a step forward of the American Association for the Study of Liver Diseases","volume":"12","author":"Fortea","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.avsg.2025.06.026_bib32","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.avsg.2025.06.026_bib33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.avsg.2025.06.026_bib34","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.avsg.2025.06.026_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.avsg.2025.06.026_bib36","first-page":"762","article-title":"Reduced-dose apixaban and dabigatran in patients with advanced liver cirrhosis and venous thromboembolism: a case series","volume":"131","author":"Weronska","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.avsg.2025.06.026_bib37","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.avsg.2025.06.026_bib38","article-title":"Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment","volume":"85","author":"Frost","year":"2009","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.avsg.2025.06.026_bib39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/dmd.117.079624","article-title":"Apixaban and rosuvas--tatin pharmacokinetics in nonalcoholic fatty liver disease","volume":"46","author":"Tirona","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.avsg.2025.06.026_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.avsg.2025.06.026_bib41","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/ageing\/afu074","article-title":"Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England","volume":"43","author":"Abohelaika","year":"2014","journal-title":"Age Ageing"},{"key":"10.1016\/j.avsg.2025.06.026_bib42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12913-019-4711-z","article-title":"Modeling patients' time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants","volume":"19","author":"Leminen","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.avsg.2025.06.026_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24311","article-title":"Cost-effectiveness and budget impact analysis of apixaban and rivaroxaban versus warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) in Iran","volume":"47","author":"Tajik","year":"2024","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.avsg.2025.06.026_bib44","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/CEOR.S317078","article-title":"Cost-effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among Finnish patients with non-valvular atrial fibrillation","volume":"13","author":"Hallinen","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.avsg.2025.06.026_bib45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40256-016-0204-1","article-title":"Cost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with atrial fibrillation: a Greek perspective","volume":"17","author":"Athanasakis","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.avsg.2025.06.026_bib46","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1080\/03007995.2022.2115772","article-title":"Risk of stroke\/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis","volume":"38","author":"Amin","year":"2022","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.avsg.2025.06.026_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14737167.2024.2398487","article-title":"Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States","volume":"25","author":"Mohan","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509625004492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509625004492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:46:07Z","timestamp":1762299967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509625004492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":47,"alternative-id":["S0890509625004492"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2025.06.026","relation":{},"ISSN":["0890-5096"],"issn-type":[{"type":"print","value":"0890-5096"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bayesian Network Meta-Analysis of Randomized Controlled Trials Comparing the Efficacy of Diverse Interventions in Preventing Portal Venous System Thrombosis Following Splenectomy in Patients with Liver Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2025.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}